Genitourinary Syndrome of Menopause (GSM): Why It Only Affects Adults, Not Children

What GSM Actually Is, and Why the Word "Menopause" Is Not an Accident

GSM is a chronic, progressive condition caused by the loss of estrogen's biological effects on the vulva, vagina, urethra, and bladder trigone. The term replaced "vulvovaginal atrophy" in 2014 because it more accurately captures the full genitourinary picture.

The 2022 Menopause Society position statement on GSM defines GSM as "a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra, and bladder." That definition contains its own exclusion criterion: you need a prior state of estrogen sufficiency, followed by its withdrawal. A child who has never had adult estrogen levels cannot lose something she never had.

The Biology That Makes GSM an Adult-Only Condition

Estrogen receptors alpha and beta are distributed throughout the lower urogenital tract. When circulating estradiol falls below approximately 50 pg/mL, which is what happens at menopause, those receptors are no longer adequately stimulated. The consequences are measurable and tissue-specific.

Vaginal epithelium thins from a rugated, glycogen-rich, lactobacillus-colonized surface to a thin, pale, fragile one. Research published in Menopause confirms that vaginal pH rises from the premenopausal range of 3.8 to 4.5 up to 5.0 or higher as lactobacilli die off and glycogen production falls. The urethra, which shares embryologic origin with the vagina, also loses collagen support, contributing to urgency, frequency, and recurrent urinary tract infections.

A pre-pubertal child has low estrogen, but her urogenital tissues are developmentally calibrated to that hormonal environment. She is not experiencing withdrawal. Her tissues have not been conditioned by years of estrogen exposure and then deprived of it. That distinction is the entire mechanistic reason GSM does not exist in children.

What Vulvovaginal Complaints in Children Actually Are

When girls present with vulvar irritation, discharge, or dysuria, the differential diagnosis is entirely different from GSM. ACOG guidelines note that prepubertal vulvovaginitis is typically caused by poor perineal hygiene, chemical irritants (bubble baths, detergents), non-specific bacterial overgrowth, or occasionally a foreign body. Lichen sclerosus, while it can affect girls, is a separate autoimmune condition unrelated to estrogen withdrawal. Sexual abuse must always be considered and excluded appropriately.

None of those conditions involve atrophic epithelial thinning driven by estrogen deficiency. Treating a child's vulvovaginitis with vaginal estrogen would be inappropriate and clinically incorrect. The distinction matters.

How GSM Develops Across the Adult Life Stages

GSM is not a switch that flips at the last menstrual period. It develops on a continuum tied to how quickly and how far estrogen falls.

Perimenopause: When GSM Often Begins

Perimenopause can last four to eight years before the final menstrual period. During this window, ovarian estradiol output becomes erratic and periodically low. A 2021 study in the Journal of Clinical Endocrinology and Metabolism documented that genitourinary symptoms begin in a substantial proportion of women while they are still having irregular cycles, not after menopause is confirmed.

Vaginal dryness during intercourse, mild urgency, and recurrent bacterial vaginosis are early signals that often go unaddressed because many clinicians, and women themselves, associate GSM only with post-menopause. If you are in your mid-to-late 40s with irregular periods and new-onset dryness or painful sex, GSM may already be beginning.

Post-Menopause: Progressive Without Treatment

After menopause (defined as 12 consecutive months without a period), estradiol levels settle below 20 pg/mL in most women. At this stage, GSM symptoms worsen over time without intervention. This is a critical difference from vasomotor symptoms like hot flashes, which often diminish on their own after a few years. GSM does not self-resolve.

The SWAN study, which followed over 3,000 women across the menopausal transition, found that vaginal dryness prevalence increased from 4% in pre-menopause to over 47% in late post-menopause. Dyspareunia followed a similar trajectory. Without treatment, the tissue changes are cumulative.

Premature Ovarian Insufficiency: GSM Before 40

Premature ovarian insufficiency (POI) affects approximately 1% of women under age 40. These women experience menopause-level estrogen deficiency decades earlier than expected. GSM can therefore develop in a woman's 20s or 30s if POI is present or if bilateral oophorectomy has been performed. This is not a condition of old age. It is a condition of estrogen loss, regardless of chronological age.

Women with POI are at elevated risk for more severe and faster-progressing GSM because the duration of estrogen deprivation is longer over a lifetime.

Postpartum and Lactation: Transient GSM-Like Changes

This is a life stage that gets insufficient attention. After delivery, estradiol plummets to near-menopausal levels, particularly in women who are exclusively breastfeeding. Prolactin suppresses the hypothalamic-pituitary-ovarian axis, keeping estrogen low for the duration of lactation. Research in Obstetrics and Gynecology demonstrated that exclusively breastfeeding postpartum women show measurable increases in vaginal pH, thinning of vaginal epithelium, and reduced lubrication that are histologically similar to early GSM.

These changes are transient and typically resolve when lactation ends and menstrual cycles resume. However, they are real, they cause dyspareunia and dryness, and they are relevant to clinical counseling. Low-dose vaginal estrogen in lactating women has not been shown to significantly affect breast milk composition or infant estradiol levels, though data remain limited and individualized discussion with a clinician is warranted.

The Symptoms of GSM in Adult Women: A Full Genitourinary Picture

GSM is not just "dryness." That framing causes women to underreport and providers to undertreat.

The Menopause Society categorizes GSM symptoms across three domains.

Vulvovaginal symptoms: dryness, irritation, burning, discharge, and decreased lubrication with arousal.

Sexual symptoms: dyspareunia (painful intercourse), reduced sensitivity, impaired arousal, and post-coital bleeding from friable epithelium.

Urinary symptoms: urgency, frequency, dysuria, recurrent urinary tract infections, and stress or urgency incontinence.

Up to 84% of post-menopausal women report at least one symptom from this cluster, yet fewer than 25% discuss them with a healthcare provider, often because of embarrassment or the misconception that these symptoms are simply an inevitable and untreatable part of aging. They are not inevitable, and they are not untreatable.

Why the Pediatric Comparison Is Clinically Instructive (Not Just Academic)

Clinicians who understand why GSM cannot occur in children develop a sharper mental model of what GSM actually requires to exist. That model has three components:

1. A period of adequate estrogen exposure sufficient to condition urogenital tissues to estrogen dependence.
2. A sustained fall in estrogen below the threshold needed to maintain that tissue architecture.
3. Progressive, cumulative tissue remodeling in the absence of that estrogenic support.

A child satisfies none of these three conditions. A post-menopausal woman satisfies all three. A perimenopausal woman satisfies the first and is moving through the second. A postpartum breastfeeding woman temporarily satisfies the second but will reverse it.

This three-part framework is useful in clinical practice because it explains why:

• GSM requires long-term management, not a short course of treatment.
• Tissue effects are largely reversible with estrogen restoration, but only if treatment is sustained.
• Women who use vaginal estrogen for a year and then stop will see symptoms return.
• Non-hormonal vaginal moisturizers reduce symptoms but do not reverse the underlying epithelial changes.

Treating GSM as a temporary problem is one of the most common clinical errors. The child-versus-adult comparison makes clear that GSM will persist for as long as estrogen deficiency persists, which for most women means the rest of their lives after menopause.

Diagnosing GSM: What the Clinical Exam Shows

GSM is diagnosed clinically. No blood test is required, though vaginal pH measurement and microscopy (maturation index) can support the diagnosis.

On examination, findings include:

• Pale, smooth, dry vaginal walls with loss of rugae
• Friable epithelium that may bleed on contact
• Narrowing of the introitus
• Loss of labial fullness
• Urethral caruncle or meatal prominence
• Vaginal pH above 5.0

ACOG Practice Bulletin 141 recommends a symptom-based diagnosis in the appropriate clinical context. A woman over 45 with dryness, dyspareunia, and urinary urgency in the setting of irregular or absent menses has GSM until proven otherwise. Vaginal cytology showing a shift toward parabasal cells confirms estrogen deprivation at the tissue level.

Conditions That Can Mimic GSM in Adult Women

Not every case of vulvovaginal discomfort in a menopausal woman is GSM. Conditions that can coexist with or mimic GSM include:

Lichen Sclerosus

Lichen sclerosus (LS) is an autoimmune condition causing white, parchment-like skin changes, intense itch, and architectural distortion of the vulva. It can occur in post-menopausal women and is more common in that group, but it also affects pre-pubertal girls and women of reproductive age. Estrogen deficiency may worsen LS symptoms but does not cause LS. LS does not respond to vaginal estrogen. Its primary treatment is high-potency topical corticosteroids.

Contact Dermatitis and Irritant Vulvitis

Soaps, laundry detergents, panty liners, synthetic fabrics, and some topical medications cause contact irritation that mimics GSM. This is a common misdiagnosis in both directions: women with GSM attributed to "sensitivity" who never receive estrogen treatment, and women with contact dermatitis treated unnecessarily with estrogen.

Recurrent Vulvovaginal Candidiasis

Post-menopausal women on systemic hormone therapy containing progestins, or women with diabetes, are at elevated risk for recurrent yeast. The symptoms overlap with GSM. Culture confirmation before escalating treatment is good practice.

Pelvic Floor Dysfunction

Vaginismus, pelvic floor hypertonicity, and provoked vestibulodynia cause dyspareunia and may worsen in the setting of estrogen deficiency, but they require pelvic floor physical therapy as part of management, not estrogen alone.

GSM Treatment in Adult Women, by Life Stage

Treatment is matched to symptom severity, life stage, and personal preference. The guiding principle is that local vaginal estrogen is highly effective, minimally absorbed, and appropriate for most women including many with a history of estrogen-sensitive cancer (in consultation with the treating oncologist).

Local Vaginal Estrogen

Low-dose vaginal estrogen is available as a cream (conjugated estrogens 0.625 mg/g or estradiol 0.01%), a ring (estradiol acetate 0.0075 mg/day), or a vaginal tablet or insert (estradiol 4 or 10 mcg). A 2018 Cochrane review of 30 trials found that all formulations of local vaginal estrogen are similarly effective for GSM symptoms, with low systemic absorption and no significant safety signal for cardiovascular disease or breast cancer at approved doses.

Systemic estradiol levels with low-dose vaginal estrogen remain below 20 pg/mL in most users, within the normal post-menopausal range. This is why a progestogen is not routinely required alongside vaginal-only estrogen therapy at low doses in women with an intact uterus, though clinical judgment applies.

Ospemifene

Ospemifene 60 mg daily is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in vaginal tissue. It is taken orally and approved for moderate-to-severe dyspareunia and dryness due to GSM. A 52-week trial published in Menopause showed sustained improvement in vaginal pH, maturation index, and dyspareunia scores with a safety profile comparable to placebo for breast and cardiovascular endpoints. It carries a mild increase in vasomotor symptom risk and is contraindicated in women with known or suspected estrogen-dependent tumors or active venous thromboembolic disease.

Intravaginal Dehydroepiandrosterone (Prasterone)

Prasterone (DHEA) 6.5 mg vaginal insert daily is converted locally to both estrogen and androgen in vaginal tissue. FDA approval was based on the AMETHYST trial showing significant improvement in dyspareunia and vaginal dryness versus placebo. It is an option for women who prefer to avoid estrogen-labeled products or who have concerns about systemic estrogen exposure.

Non-Hormonal Options

Vaginal moisturizers (polycarbophil-based or hyaluronic acid-based) used regularly three to five times per week reduce dryness and lower vaginal pH modestly. Silicone-based lubricants used at the time of intercourse reduce friction and dyspareunia. These options do not reverse the underlying epithelial changes but are useful as standalone therapy for mild symptoms or as adjuncts to hormonal treatment.

Pelvic floor physical therapy is underused and highly effective for the dyspareunia and urinary symptoms of GSM, particularly when pelvic floor dysfunction coexists.

PCOS, Endometriosis, and Premature Estrogen Loss: Conditions That Shape GSM Risk

Several conditions specific to women alter the GSM risk trajectory.

Women with premature ovarian insufficiency (POI), whether from autoimmune disease, chemotherapy, or idiopathic causes, face decades of estrogen deficiency before the typical menopausal window. ACOG Committee Opinion 698 recommends systemic hormone therapy (not just vaginal estrogen) in women with POI until at least the average age of natural menopause, for both genitourinary and bone and cardiovascular protection.

Women with endometriosis who have undergone surgical or medical oophorectomy (including GnRH agonist therapy creating a hypoestrogenic state) may develop GSM at reproductive age. GnRH agonists like leuprolide create profound estrogen suppression; vaginal dryness and dyspareunia are among the most common reasons women discontinue these agents.

Women with PCOS generally maintain adequate estrogen production into natural menopause and do not face elevated early GSM risk on that basis. However, women with PCOS who undergo ovarian surgery or who have anovulatory cycles with very low estrogen windows may experience intermittent genitourinary changes.

Women with a history of breast cancer who are on aromatase inhibitors face some of the most severe GSM of any population, because aromatase inhibitors suppress estradiol to near-undetectable levels. A 2022 ACOG Practice Bulletin addresses vaginal estrogen use in this setting and notes that low-dose vaginal estrogen is generally considered appropriate after discussion with the oncologist, though ospemifene and prasterone may be preferred by women and oncologists who wish to minimize any theoretical systemic estrogen exposure.

The Evidence Gap: What We Do Not Know Well Enough

Women have been underrepresented in genitourinary research. Several gaps remain.

Maturation index thresholds are derived from older datasets with limited racial and ethnic diversity. Vaginal microbiome data in post-menopausal women of color are sparse. A 2020 analysis in Menopause found that Black and Hispanic post-menopausal women report vaginal symptoms at rates comparable to white women but are less likely to receive treatment, a disparity that reflects both provider bias and patient barriers to disclosure.

Long-term data on prasterone and ospemifene beyond two years are limited. We do not yet have adequately powered trials comparing these agents head-to-head. The choice between them remains based on patient preference, cost, and individual tolerability rather than clear superiority data.

Evidence on GSM management in transgender men on testosterone therapy, or in non-binary individuals with endogenous estrogen deficiency, is almost entirely absent from the literature. That is a research gap, not clinical permission to ignore these patients. Testosterone use in women assigned female at birth does not prevent GSM; vaginal atrophy has been reported in testosterone-treated individuals and warrants the same local estrogen approach.

Who GSM Treatment Is Right For, and Who Needs a Different Conversation

GSM treatment is appropriate for:

• Post-menopausal women with any genitourinary symptom affecting quality of life
• Perimenopausal women with early GSM symptoms and declining estrogen
• Women with POI at any age who are not already on systemic hormone therapy
• Postpartum breastfeeding women with symptomatic dryness and dyspareunia (non-hormonal first; vaginal estrogen after individualized discussion)
• Breast cancer survivors on aromatase inhibitors with bothersome GSM (after oncology consultation)

GSM treatment should be approached differently in:

• Women with undiagnosed vaginal bleeding (rule out endometrial pathology before initiating estrogen)
• Women with active pelvic floor hypertonicity where estrogen alone will not address the primary pain mechanism
• Women with confirmed LS, where high-potency steroids are the correct first-line treatment
• Women with contact dermatitis where allergen avoidance is the intervention

Children never: No child should receive vaginal estrogen for "GSM." GSM does not exist in children. If a pediatric patient has been given this diagnosis, the framing is incorrect and should be reconsidered by a pediatric gynecologist.